WO2004016749A3 - Modulation antisens de l'expression de l'acyl-coa synthetase 1 - Google Patents

Modulation antisens de l'expression de l'acyl-coa synthetase 1 Download PDF

Info

Publication number
WO2004016749A3
WO2004016749A3 PCT/US2003/025389 US0325389W WO2004016749A3 WO 2004016749 A3 WO2004016749 A3 WO 2004016749A3 US 0325389 W US0325389 W US 0325389W WO 2004016749 A3 WO2004016749 A3 WO 2004016749A3
Authority
WO
WIPO (PCT)
Prior art keywords
expression
acyl
acs1
coa synthetase
antisense modulation
Prior art date
Application number
PCT/US2003/025389
Other languages
English (en)
Other versions
WO2004016749A2 (fr
Inventor
Stuart A Ross
Original Assignee
Pharmacia Corp
Stuart A Ross
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp, Stuart A Ross filed Critical Pharmacia Corp
Priority to BRPI0313550-0A priority Critical patent/BR0313550A/pt
Priority to MXPA05001837A priority patent/MXPA05001837A/es
Priority to AU2003269962A priority patent/AU2003269962A1/en
Priority to JP2004529376A priority patent/JP2006506976A/ja
Priority to EP03751855A priority patent/EP1572713A4/fr
Priority to CA002495037A priority patent/CA2495037A1/fr
Publication of WO2004016749A2 publication Critical patent/WO2004016749A2/fr
Publication of WO2004016749A3 publication Critical patent/WO2004016749A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y602/00—Ligases forming carbon-sulfur bonds (6.2)
    • C12Y602/01—Acid-Thiol Ligases (6.2.1)
    • C12Y602/01003—Long-chain-fatty-acid-CoA ligase (6.2.1.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des composés antisens, des compositions et des méthodes permettant de moduler l'expression de l'acyl-CoA synthétase 1, jusqu'ici appelée ACS1. Lesdites compositions comprennent des composés antisens, notamment des oligonucléotides antisens, ciblés sur des acides nucléiques codant pour l'ACS1. L'invention concerne des méthodes d'utilisation desdits composés pour la modulation de l'expression de l'ACS1 et pour le traitement de maladies associées à l'expression de l'ACS1.
PCT/US2003/025389 2002-08-14 2003-08-14 Modulation antisens de l'expression de l'acyl-coa synthetase 1 WO2004016749A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
BRPI0313550-0A BR0313550A (pt) 2002-08-14 2003-08-14 modulação "antisense" da expressão de sintetase 1 de acil-coa
MXPA05001837A MXPA05001837A (es) 2002-08-14 2003-08-14 Modulacion de polaridad opuesta de la expresion de la acil-coa sintetasa 1.
AU2003269962A AU2003269962A1 (en) 2002-08-14 2003-08-14 Antisense modulation of acyl-coa synthetase 1 expression
JP2004529376A JP2006506976A (ja) 2002-08-14 2003-08-14 アシル−ＣｏＡシンテターゼ１発現のアンチセンス調節
EP03751855A EP1572713A4 (fr) 2002-08-14 2003-08-14 Modulation antisens de l'expression de l'acyl-coa synthetase 1
CA002495037A CA2495037A1 (fr) 2002-08-14 2003-08-14 Modulation antisens de l'expression de l'acyl-coa synthetase 1

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40359102P 2002-08-14 2002-08-14
US60/403,591 2002-08-14

Publications (2)

Publication Number Publication Date
WO2004016749A2 WO2004016749A2 (fr) 2004-02-26
WO2004016749A3 true WO2004016749A3 (fr) 2004-08-26

Family

ID=31888248

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/025389 WO2004016749A2 (fr) 2002-08-14 2003-08-14 Modulation antisens de l'expression de l'acyl-coa synthetase 1

Country Status (7)

Country Link
EP (1) EP1572713A4 (fr)
JP (1) JP2006506976A (fr)
AU (1) AU2003269962A1 (fr)
BR (1) BR0313550A (fr)
CA (1) CA2495037A1 (fr)
MX (1) MXPA05001837A (fr)
WO (1) WO2004016749A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006249925A1 (en) * 2005-05-24 2006-11-30 Isis Pharmaceuticals, Inc. Modulation of LMW-PTPase expression
WO2010079819A1 (fr) * 2009-01-08 2010-07-15 塩野義製薬株式会社 Composition pharmaceutique destinée au traitement de l'obésité ou du diabète
JP2015082971A (ja) * 2012-02-10 2015-04-30 国立大学法人大阪大学 Ａｃｓｌ１に対するアンチセンスオリゴヌクレオチド
WO2015020194A1 (fr) * 2013-08-09 2015-02-12 国立大学法人大阪大学 Oligonucléotide antisens contre acsl1
EP3603648A4 (fr) 2017-03-29 2020-12-30 Shionogi & Co., Ltd Complexe de médicament d'acide nucléique et de lipide multiramifié
WO2021020412A1 (fr) 2019-07-30 2021-02-04 塩野義製薬株式会社 Médicament à base d'acide nucléique ciblant le murf1
US20230322840A1 (en) 2020-06-15 2023-10-12 Liid Pharmaceuticals, Inc. Bridged nucleoside and nucleotide

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346398B1 (en) * 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
US6133246A (en) * 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
EP1456400A4 (fr) * 2001-12-19 2005-09-14 Exelixis Inc Modulation de la signalisation des recepteurs de l'insuline par ciblage de genes de facl (acyl-coa synthetase))

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CANTU ET AL: "The human palmitoyl-CoA ligase (FACL2) gene maps to the chromosome 4q34-q35 region by fluorescence in situ hybridization (FISH) and somatic cell hybrid panels", GENOMICS, vol. 28, May 1995 (1995-05-01), pages 600 - 602, XP002122292 *
GAO ET AL: "Transformation of pear (Pyrus communis cv. "La France") with genes involved in ethylene biosynthesis", ACTA HORTICULTURAE, vol. 625, January 2003 (2003-01-01), XP008034175 *
MITIOUCHKINA ET AL: "Modification of chrysanthemum plant and flower architecture by Rolc gene from agrobacterium rhizogenes introduction", ACTA HORTICULTURAE, vol. 575, January 2000 (2000-01-01), pages 163 - 169, XP008034174 *
MUOIO ET AL: "Acyl-CoAs are functionally channeled in liver: potential role of acyl-CoA synthetase", AM. J. PHYSIOL. ENDOCRINOL. METAB., vol. 279, 2000, pages E1366 - E1373, XP002978517 *
SUZUKI ET AL: "Structure and regulation of rat long-chain acyl-CoA synthetase", J. OF BIOLOGICAL CHEMISTRY, vol. 265, no. 15, 25 May 1990 (1990-05-25), pages 8681 - 8685, XP002978516 *
WONG ET AL: "Repression of chilling-induced ACC accumulation in transgenic citrus by over-production of antisense 1-aminocyclopropane-1-carboxylate synthase RNA", PLANT SCIENCE, vol. 161, no. 5, October 2001 (2001-10-01), pages 969 - 977, XP002978518 *

Also Published As

Publication number Publication date
JP2006506976A (ja) 2006-03-02
WO2004016749A2 (fr) 2004-02-26
AU2003269962A8 (en) 2004-03-03
AU2003269962A1 (en) 2004-03-03
EP1572713A2 (fr) 2005-09-14
EP1572713A4 (fr) 2006-05-24
MXPA05001837A (es) 2005-04-19
BR0313550A (pt) 2006-06-13
CA2495037A1 (fr) 2004-02-26

Similar Documents

Publication Publication Date Title
WO2005049630A3 (fr) Modulation antisens de l'expression de la proteine de type kinesine 1
WO2002036743A3 (fr) Modulation antisens de l'expression de calreticuline
WO2002092772A3 (fr) Modulation antisens de l'expression de ptp1b
WO2004044181A3 (fr) Modulation antisens de l'expression d'apolipoproteine b
EP1190099A4 (fr) Modulation antisens de l'expression de pi3k p85
WO2004071407A3 (fr) Modulation antisens de l'expression de ptp1b
WO2004011610A3 (fr) Modulation antisens de l'expression de kinase de type polo
WO2003097662A8 (fr) Modulation antisens de l'expression de l'apolipoproteine b
WO2002010378A3 (fr) Modulation antisens de l'expression de ptp1b
WO2003046132A3 (fr) Modulation antisens de l'expression du myd88
WO2003053341A3 (fr) Modulation antisens de l'expression de ship-1
WO2002095053A3 (fr) Modulation antisens de l'expression des src-c
EP1250347A4 (fr) Modulation antisens de l'expression de akt-3
WO2003088921A3 (fr) Modulation antisens de l'expression d'hydroxysteroide 11-beta deshydrogenase 1
WO2003052062A3 (fr) Modulation antisens de l'expression de cd36l1
WO2004010956A3 (fr) Modulation par antisens d'expression de lar
WO2004016749A3 (fr) Modulation antisens de l'expression de l'acyl-coa synthetase 1
WO2003099224A3 (fr) Modulation antisens de l'expression de la kinesine de type 1
EP1235924A4 (fr) Modulation antisens de l'expression de l'activateur du recepteur de facteur kappa b nucleaire (rank)
WO2003027229A3 (fr) Modulation antisens de l'expression de rip2
WO2003040161A3 (fr) Modulation antisens de l'expression du facteur de transcription activateur 3
WO2004014299A3 (fr) Modulation antisens de l'expression de la resistine
WO2003031576A3 (fr) Modulation antisens de l'expression de l'inhibiteur kappa b kinase-gamma
WO2003099204A3 (fr) Modulation anti-sens de l'expression inhibiteur kappa b kinase-beta
WO2004015126A3 (fr) Modulation antisens de l'expression d'edg

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2495037

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/001837

Country of ref document: MX

Ref document number: 2004529376

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003751855

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003751855

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003751855

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0313550

Country of ref document: BR